©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
World J Psychiatry. Mar 19, 2026; 16(3): 114882
Published online Mar 19, 2026. doi: 10.5498/wjp.v16.i3.114882
Published online Mar 19, 2026. doi: 10.5498/wjp.v16.i3.114882
Critical commentary on initial lurasidone dosing strategies in acute schizophrenia
Hao-Yu Xing, Department of Medical Engineering, The Affiliated Mental Health Center and Hangzhou Seventh People’s Hospital, Zhejiang University School of Medicine, Hangzhou 310013, Zhejiang Province, China
Juan Yan, Quality Control Office, The Affiliated Mental Health Center and Hangzhou Seventh People’s Hospital, Zhejiang University School of Medicine, Hangzhou 310013, Zhejiang Pro
Author contributions: Xing HY wrote the original draft; Yan J contributed to the conceptualization, writing, reviewing, and editing; Xing HY and Yan J participated in drafting the manuscript. All authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Juan Yan, MD, Professor, The Affiliated Mental Health Center and Ha
Received: October 9, 2025
Revised: November 1, 2025
Accepted: December 23, 2025
Published online: March 19, 2026
Processing time: 146 Days and 0.4 Hours
Revised: November 1, 2025
Accepted: December 23, 2025
Published online: March 19, 2026
Processing time: 146 Days and 0.4 Hours
Core Tip
Core Tip: Liu et al provide evidence challenging the conventional “start low, go slow” approach for lurasidone in acute schizophrenia. Their trial suggests that initiating treat